SPONSORED CONTENT
The 340B Drug Pricing Program is at a crossroads, facing increased scrutiny, manufacturer restrictions, and ongoing legal battles. In this must-watch webinar, industry experts Ted Slafsky (340B Report), Emily Cook (McDermott, Will & Emery), and Nicole Shoquist (JPS Health Network) break down the
…